Implementation of Oncotype Dx to Guide Chemotherapy Sparing for Women with Postmenopausal N1-3, ER-positive, HER-2-negative Breast Cancer

被引：0
|
作者：
Rajakumar, L. [1 ]
Glendenning, J. [1 ]
Hall, J. [1 ]
Burcombe, R. [1 ]
McCormick, G. [1 ]
Hegarty, G. [1 ]
Harper-Wynne, C. [1 ]
Brown, B. [1 ]
Moss, C. [1 ]
Thomas, C. [1 ]
Jyothirmayi, R. [1 ]
Osman, M. [1 ]
Nikiforidis, L. [1 ]
机构：
[1] Maidstone & Tunbridge Wells NHS Trust, Maidstone, Kent, England
来源：
CLINICAL ONCOLOGY | 2024年 / 36卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E111 / E111
页数：1
相关论文
共 50 条
  • [1] Utilization of oncotype DX in node-negative, ER-positive breast cancer patients
    Patel, H.
    Hook, K.
    Kaplan, C.
    Davidson, R.
    DeMichele, A.
    Fox, K. R.
    Domchek, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] The Oncotype Dx Assay in ER-Positive, HER2-Negative Breast Cancer Patients: A Real Life Experience from a Single Cancer Center
    Thibodeau, Stephane
    Voutsadakis, Ioannis A.
    EUROPEAN JOURNAL OF BREAST HEALTH, 2019, 15 (03) : 163 - 170
  • [3] Discordant classification and outcomes between Prosigna and Oncotype Dx Recurrence Score for ER-positive, HER2-negative, node-negative breast cancer
    Sestak, Ivana
    Ferree, Sean
    Shemesh, Itay
    Buckingham, Wesley
    Cuzick, Jack
    Dowsett, Mitchell
    CANCER RESEARCH, 2020, 80 (04)
  • [4] Impact of Oncotype DX on Treatment Decisions in ER-Positive, Node-Negative Breast Cancer with Histologic Correlation
    Biroschak, Julianne R.
    Schwartz, Gordon F.
    Palazzo, Juan P.
    Toll, Adam D.
    Brill, Kristin L.
    Jaslow, Rebecca J.
    Lee, Sun Yong
    BREAST JOURNAL, 2013, 19 (03): : 269 - 275
  • [5] Neoadjuvant chemotherapy versus neoadjuvant hormonal therapy in postmenopausal women with ER-positive, HER2/neu negative locally advanced breast cancer
    Ambros, Tadeu Frantz
    Reis, Isildinha M.
    Bagga, Dilprit
    Villasboas, Jose Caetano
    Blieden, Clifford
    Sujoy, Victoria
    Wright, Jean L.
    Saigal, Kunal
    Fernandez, Carmen Gomez
    Hurley, Judith
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] Reply to: Prediction of benefit from chemotherapy in ER-positive/HER2-negative breast cancer
    Goldhirsch, A.
    Coates, A. S.
    ANNALS OF ONCOLOGY, 2014, 25 (03) : 755 - 755
  • [7] Elacestrant for ER-Positive HER2-Negative Advanced Breast Cancer
    Hageman, Elizabeth
    Lussier, Mia E.
    ANNALS OF PHARMACOTHERAPY, 2024, 58 (08) : 849 - 856
  • [8] Elacestrant in advanced ER-positive, HER2-negative breast cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (01) : 17 - 17
  • [9] Endo Predict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer
    Bertucci, Francois
    Finetti, Pascal
    Viens, Patrice
    Birnbaum, Daniel
    CANCER LETTERS, 2014, 355 (01) : 70 - 75
  • [10] Palbociclib and letrozole for ER-positive, HER2-negative advanced breast cancer
    Abraham, Jame
    Mechcatie, Elizabeth
    JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2015, 13 (03): : 83 - 86
12345